Please login to the form below

pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib , an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

Baxalta and CTI complete filing for Jakafi rival in US

Myelofibrosis candidate pacritinib aiming for accelerated approval. Baxalta and CTI Biopharma have completed their rolling regulatory submission for their myelofibrosis candidate pacritinib in the US, and are aiming for accelerated approval.
Baxter and CTI's Jakafi rival clears phase III trial

Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal. ... year. The trial will also compare pacritinib to best available therapy, but in this case that will include JAK2 inhibitors.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Specifically, the company's chief executive James Bianco maintains that pacritinib is less prone to causing reductions in blood platelet counts, which can limit treatment. ... he added, noting that additional data on pacritinib will be presented at the
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... The Sanofi decision was taken following reported cases consistent with Wernicke's encephalopathy in patients participating in the clinical trials. Pacritinib, an oral therapy, is

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Director, Healthcare Marketing Agency: Salary TBC

Digital Account Director: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Great salary and benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....